Radiation therapy equipment developer RefleXion has closed a financing round worth $80 million to further develop the company's biology-guided radiotherapy (BgRT) technology.
The financing round included the company's existing investors, as well as new investors Ascension Ventures, Catalio Capital Management, Sixty Degree Capital, and Hillenbrand Capital Partners.
RefleXion's BgRT technology last year received a breakthrough device designation from the U.S. Food and Drug Administration (FDA) for use in treating lung tumors. The company's RefleXion X1 has been cleared by the FDA to deliver conventional radiation therapy such as stereotactic body radiation therapy, stereotactic radiosurgery, and intensity-modulated radiation therapy. Clinical applications for BgRT are pending regulatory review.
